Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Business Insider6d
Precision BioSciences: Undervalued Gene Editing Innovator with Promising Financial and Clinical Prospects
Precision BioSciences has a solid financial position with a significant cash reserve, extending its operational runway well into the latter half of 2026. Upcoming clinical milestones, particularly in ...